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2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) is a chemically modified cyclic oligosaccha-
ride produced from starch that is commonly used as an excipient. Although HP-β-CD has 
been suggested as a potential adjuvant for vaccines, its immunological properties and 
mechanism of action have yet to be characterized. In the present study, we investigated 
the maturation and activation of human dendritic cells (DCs) treated with HP-β-CD. 
We found that DCs stimulated with HP-β-CD exhibited a remarkable upregulation of 
costimulatory molecules, MHC proteins, and PD-L1/L2. In addition, the production of 
cytokines, such as TNF-α, IL-6, and IL-10, was modestly increased in DCs when treated 
with HP-β-CD. Furthermore, HP-β-CD-sensitized DCs markedly induced the prolifer-
ation and activation of autologous T lymphocytes. HP-β-CD also induced a lipid raft 
formation in DCs. In contrast, filipin, a lipid raft inhibitor, attenuated HP-β-CD-induced 
DC maturation, the cytokine expression, and the T lymphocyte-stimulating activities. 
To determine the in  vivo relevance of the results, we investigated the adjuvanticity of 
HP-β-CD and the modulation of DCs in a mouse footpad immunization model. When 
mice were immunized with ovalbumin in the presence of HP-β-CD through a hind foot-
pad, serum ovalbumin-specific antibodies were markedly elevated. Concomitantly, DC 
populations expressing CD11c and MHC class II were increased in the draining lymph 
nodes, and the expression of costimulatory molecules was upregulated. Collectively, our 
data suggest that HP-β-CD induces phenotypic and functional maturation of DCs mainly 
mediated through lipid raft formation, which might mediate the adjuvanticity of HP-β-CD.
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inTrODUcTiOn
Cyclodextrins are cyclic oligosaccharides composed of sugar molecules. These oligosaccharides 
consist of 6, 7, or 8 α-d-glucopyranose units bound via α-1,4-glycosidic linkages, namely, α-, β-, or 
γ-cyclodextrin, respectively. Cyclodextrins exhibit a bucket-shaped structure with a hydrophobic 
central cavity and a hydrophilic exterior (1). Cyclodextrins can efficiently form water-soluble inclu-
sion complexes with hydrophobic molecules, which enhances the solubility and bioavailability of 
many insoluble compounds (2, 3). In addition, cyclodextrins improve and prolong the medicinal 
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effects of drugs by controlling compound release, increasing 
their stability, and regulating the metabolism of the incorporated 
molecules (4). Due to these physicochemical properties, cyclo-
dextrins are commonly utilized as excipients of pharmaceutical 
agents, food products, and cosmetics.
β-Cyclodextrin and some of its derivatives are widely used 
additives of commercial drugs because they are easy to produce, 
belong to generally recognized as safe (GRAS) materials for 
humans, and have improved solubility compared with the other 
cyclodextrins (4, 5). 2-Hydroxypropyl-β-cyclodextrin (HP-β-CD) 
is a chemically modified derivative of β-cyclodextrin that exhibits 
an enhanced safety profile compared with its naturally occurring 
parent compound (4). HP-β-CD is used as an excipient for cardiac 
dysrhythmia, inflammation, and fungal disease medications (6). 
Furthermore, HP-β-CD has been proposed as a vaccine adjuvant 
because it markedly enhances humoral immune responses to an 
influenza vaccine without any adverse effects (7). However, the 
immunological properties and action mechanism of HP-β-CD 
need to be further characterized for the human use.
Dendritic cells (DCs) are professional antigen-presenting cells 
that bridge the innate and adaptive immunities. Immature DCs 
are characterized by high endocytic activity coincident with a low 
expression of costimulatory molecules and cytokines (8). When 
immature DCs meet microbial antigens or damage-associated 
molecular patterns, they begin the process of maturation (8, 9). 
This process is accompanied by upregulation of (i) MHC associ-
ated with the antigen; (ii) costimulatory molecules including 
CD40, CD80, and CD86; and (iii) inflammatory cytokines such 
as IL-12, IL-6, and TNF-α (10). These phenotypic changes opti-
mize conditions for T lymphocyte activation and differentiation 
(11, 12). Since mature DCs potently stimulate adaptive immunity 
better than immature DCs, many vaccine adjuvants currently 
under development are designed to efficiently induce functional 
maturation and activation of DCs (13–15). In the present 
study, we investigated immunological function of HP-β-CD by 
determining its ability to mature and activate DCs leading to the 
induction of adaptive immunity.
MaTerials anD MeThODs
reagents and chemicals
2-Hydroxypropyl-β-cyclodextrin was purchased from Sigma-
Aldrich (Saint Louis, MO, USA). Ficoll-Paque PLUS was 
obtained from GE Healthcare (Uppsala, Sweden). Fetal bovine 
serum (FBS) was purchased from GIBCO (Grand Island, NY, 
USA). RPMI-1640 medium and HyClone™ penicillin–strep-
tomycin solution were from HyClone (Logan, UT, USA). Anti-
human CD14 magnetic beads (clone: MΦP9) and anti-human 
CD3 magnetic beads (clone: HIT3a) were purchased from 
BD Biosciences (San Diego, CA, USA). Recombinant human 
granulocyte macrophage-colony stimulating factor (GM-CSF) 
and IL-4 were purchased from R&D Systems (Minneapolis, 
MN, USA) and CreaGene (Sungnam, Korea), respectively. 
Recombinant murine GM-CSF was obtained from CreaGene. 
3,3′,5,5′-Tetramethylbenzidine (TMB) substrate and enzyme-
linked immunosorbent assay (ELISA) kits for the quantification 
of human TNF-α, IL-6, IL-12p70, and IL-10, and mouse TNF-α 
and IL-6 were purchased from BioLegend (San Diego, CA, USA). 
5,6-Carboxyfluorescein diacetate succinimidyl ester (CFDA-SE) 
and the Vybrant® Alexa Fluor® 594 lipid raft-labeling kit were 
obtained from Molecular Probes (Eugene, OR, USA). Filipin, 
bovine serum albumin (BSA), 2,2,2-tribromoethanol, 2-methyl-
2-butanol, ovalbumin (OVA), and red blood cell (RBC)-lysis 
buffer were purchased from Sigma-Aldrich. Luria Bertani 
broth and Bacto™ Agar were purchased from BD Biosciences. 
FITC-labeled anti-human CD80 (clone: 2D10), PE-labeled 
anti-human CD83 (clone: HB15e), APC-labeled anti-human 
CD86 (clone: IT2.2), APC-labeled anti-PD-L1 (clone: 29E.2A3), 
PE-labeled anti-human PD-L2 (clone: 24F.10C12), APC-labeled 
anti-human CD25 (clone: BC96), PE-labeled anti-human CD4 
(clone: RPA-T4), and PE-labeled anti-human CD8 (clone: RPA-
T8) antibodies were purchased from BioLegend. FITC-labeled 
anti-human HLA-DR, DP, DQ (clone: Tu39) antibody for MHC 
class II, FITC-labeled anti-mouse CD86 (clone: GL-1) antibody, 
PE-labeled anti-mouse CD80 (clone: 16-10A1) antibody, PerCP-
labeled anti-mouse CD11c (clone: N418) antibody, and FITC-
labeled anti-mouse I-Ab (clone: 25-9-17) antibody for MHC 
class II were obtained from BD Biosciences. All isotype-matched 
antibodies were purchased from BD Biosciences or BioLegend. 
Horseradish peroxidase (HRP)-conjugated anti-mouse total IgG, 
anti-mouse IgG1, and anti-mouse IgG2a were purchased from 
Southern Biotech (Birmingham, AL, USA).
Preparation of human  
Monocyte-Derived Dcs
Human peripheral blood samples donated by healthy adult male 
subjects (n =  15) were provided from the Korean Red Cross 
(Seoul, Korea) after obtaining informed consent. All experi-
ments using human blood were conducted under the approval 
of the Institutional Review Board of Seoul National University. 
The peripheral blood was diluted in phosphate-buffered saline 
(PBS) and overlaid on the Ficoll-Paque PLUS, and peripheral 
blood mononuclear cells (PBMCs) were isolated by density-
gradient centrifugation as previously described (16, 17). PBMCs 
were washed with PBS three times to remove platelets and the 
remaining Ficoll. To isolate CD14+ monocytes, PBMCs were 
incubated with anti-human CD14 magnetic beads for 30 min at 
room temperature. The cells were separated on a magnetic field, 
and then CD14+ cells were enriched by positive selection. CD14+ 
monocytes were suspended at a concentration of 2 × 106 cells/
ml in RPMI-1640 medium supplemented with 10% FBS and 1% 
penicillin–streptomycin solution. The isolated monocytes were 
differentiated into immature DCs in the presence of human 
recombinant GM-CSF (5 ng/ml) and IL-4 (10 ng/ml) for 6 days. 
Cell culture medium supplemented with GM-CSF and IL-4 was 
added every 3 days.
Preparation of hKec
Escherichia coli BL21 (DE3) strain obtained from Stratagene 
(La Jolla, CA, USA) was cultured in Luria Bertani broth at 37°C 
until reaching mid-log phase and then harvested by centrifugation. 
The harvested bacterial cells were resuspended in PBS and killed 
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by heating at 60°C for 1 h. To confirm the complete killing, the 
heat-treated E. coli was plated onto Luria Bertani agar plates and 
cultured overnight at 37°C. No bacterial colonies were observed.
analysis of Dc Phenotypes
Mouse BM-DCs (5 ×  105  cells/ml) were stimulated with either 
HP-β-CD (0, 0.1, or 1 mg/ml) or LPS (100 ng/ml) in the presence 
of murine GM-CSF (10  ng/ml) for 24  h. Human monocyte-
derived DCs (2.5  ×  105  cells/ml) were stimulated with either 
HP-β-CD (0, 0.1, 0.3, or 1 mg/ml) or HKEC (1 × 107 CFU/ml) 
in the presence of GM-CSF (2.5 ng/ml) and IL-4 (5 ng/ml) for 
24  h. The unstimulated or stimulated DCs were then stained 
with fluorochrome-conjugated monoclonal antibodies specific to 
CD80, CD83, CD86, MHC class II, PD-L1, or PD-L2 for 30 min 
on ice, and then the cells were washed once with PBS. The geomet-
ric mean fluorescence intensity (MFI) of each group of DCs was 
obtained by flow cytometric analysis. More than 8,500 events were 
acquired for each group, and cell debris and dead cells were gated 
out. Phenotypes of DCs were analyzed using flow cytometry with 
FACSCalibur (BD Biosciences) and FlowJo software (TreeStar, 
San Carlos, CA, USA).
cytokine Quantification
The levels of cytokines produced by DCs were quantified by 
ELISA, as previously described (18). Briefly, mouse BM-DCs 
(5  ×  105  cells/ml) were stimulated with either HP-β-CD (0, 
0.1, or 1 mg/ml) or LPS (100 ng/ml) in the presence of murine 
GM-CSF (10  ng/ml) for 24  h. Human monocyte-derived DCs 
(2.5 × 105 cells/ml) were stimulated with either HP-β-CD (0, 0.1, 
0.3, or 1 mg/ml) or HKEC (1 × 107 CFU/ml) in the presence of 
GM-CSF (2.5 ng/ml) and IL-4 (5 ng/ml) for 24 h. The levels of 
TNF-α, IL-6, IL-12p70, and IL-10 in the culture supernatants 
were measured by ELISA kits according to the manufacturers’ 
instructions.
coculture of Dcs with autologous  
T lymphocytes
To isolate CD3+ T lymphocytes, CD14+ monocyte-depleted 
PBMCs were incubated with anti-human CD3 magnetic beads 
for 30  min, and then CD3+ T lymphocytes were enriched by 
positive selection. The isolated CD3+ T lymphocytes were labeled 
with 10 μM CFDA-SE for 15 min at 37°C and washed with PBS. 
Immature DCs (2.5 × 105 cells/ml) were stimulated with either 
HP-β-CD (0, 0.1, 0.3, or 1 mg/ml) or HKEC (1 × 107 CFU/ml) in 
the presence of GM-CSF (2.5 ng/ml) and IL-4 (5 ng/ml) for 16 h. 
After removal of the culture supernatant, the DCs (5 × 104 cells) 
were cocultured with carboxyfluorescein succinimidyl ester 
(CFSE)-labeled autologous CD3+ T lymphocytes (5 × 104 cells) for 
4–5 days. To analyze DC-mediated proliferation and activation 
of T lymphocyte subsets, the cells were stained with anti-human 
CD4, anti-human CD8, or anti-human CD25 antibodies and then 
analyzed by flow cytometry.
analysis of lipid raft Formation
Dendritic cells (2.5 × 105 cells/ml) were stimulated with HP-β-CD 
(1  mg/ml) in the presence or absence of filipin (30  μg/ml) 
for 45  min. Cell staining was performed with the lipid raft-
labeling kit according to the manufacturer’s instructions. Briefly, 
unstimulated or HP-β-CD-stimulated DCs were washed once 
with ice-cold PBS and stained with Alexa Fluor® 594-conjugated 
CTB conjugate for 10  min on ice. The DCs were washed once 
with ice-cold PBS and incubated with rabbit serum containing 
anti-CTB antibodies for 10  min on ice to crosslink lipid rafts 
on the surface of the DCs. Formation of lipid raft on the DCs 
was analyzed by confocal laser scanning microscopy (Carl Zeiss 
MicroImaging GmbH, Jena, Germany). Fluorescence intensity 
of DCs was analyzed by ZEN software, Lite Edition (Carl Zeiss, 
Oberkochen, Germany).
immunization with OVa Plus hP-β-cD  
in Mice
Seven-week-old male C57BL/6 mice were purchased from Orient 
Bio (Sungnam, Korea) and maintained in a specific pathogen-free 
animal facility. All experiments using animals were conducted 
under the approval of the Institutional Animal Care and Use 
Committee of Seoul National University. Care and treatment of 
the animals were carried out in accordance with the approved 
guidelines. Mice were anesthetized by intraperitoneal injection 
of Avertin (2,2,2-tribromoethanol and 2-methyl-2-butanol) and 
administered with 20 μg OVA with or without 3 mg HP-β-CD 
through a hind footpad. The mice were maintained for 24 h or 
7 days and sacrificed to obtain the draining lymph nodes and the 
blood, respectively.
analysis of Dc activation in the Draining 
lymph nodes
Twenty-four hours after the immunization with OVA in the 
presence or absence of HP-β-CD, draining lymph nodes, includ-
ing popliteal and inguinal lymph nodes, were harvested and 
dissociated into a single cell suspension on a cell strainer (BD 
Biosciences). To analyze DC populations in the lymph nodes, 
the cells were stained with fluorochrome-conjugated antibodies 
specific to CD11c, MHC class II, CD86, and CD80 at 4°C for 
30 min. CD11c+ MHC class II+ cells in the lymph nodes and their 
phenotypic changes upon the administration of OVA in the pres-
ence or absence of HP-β-CD were analyzed by flow cytometry 
using FACSVerse (BD Biosciences).
Preparation of Mouse Bone  
Marrow-Derived Dcs
Bone marrow-derived DCs (BM-DCs) were generated as previ-
ously described (19), with minor modifications. Briefly, BM cells 
were isolated from mouse femurs and tibias, and the RBCs were 
lysed with the RBC lysis buffer. Isolated BM cells were suspended 
in RPMI-1640 medium supplemented with 10% FBS and 1% 
penicillin–streptomycin solution and plated in petri dishes at 
4 × 105 cells/ml. The BM cells were differentiated into immature 
DCs in the presence of murine recombinant GM-CSF (20 ng/ml) 
for 7 days. Cell culture medium supplemented with GM-CSF was 
added every 4 days.
FigUre 1 | hP-β-cD induces maturation of human monocyte-derived Dcs. Human CD14+ monocytes (2 × 106 cells/ml) were differentiated into immature 
DCs in the presence of GM-CSF and IL-4 for 6 days. The monocyte-derived DCs (2.5 × 105 cells/ml) were stimulated with HP-β-CD (0, 0.1, 0.3, or 1 mg/ml) in the 
presence of GM-CSF and IL-4 for 24 h. (a–F) Expression of (a,D) CD80, CD83, and CD86, (B,e) MHC class II, and (c,F) PD-L1 and PD-L2 was analyzed by flow 
cytometry. The number on each histogram indicates MFI of the DCs. (D–F) The scatter plots below the histograms indicate the average MFI of DCs ± SEM for each 
molecule (n = 5). The levels of (g) TNF-α, (h) IL-6, and (i) IL-10 in the DC culture supernatants were measured by ELISA. The scatter plots on the right side of each 
bar graph indicate the mean concentrations ± SEM of the cytokines (n = 5). HKEC (1 × 107 CFU/ml) was used as a positive control. Statistical differences between 
compared groups were analyzed by paired Student’s t-test. N.D., not detected; *P < 0.05.
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statistical analysis
The statistical significance of differences between the experi-
mental groups and the control group was analyzed using 
Student’s t-test. P-values less than 0.05 were considered sta-
tistically significant. Results are presented as mean value ± SD 
or SEM.
resUlTs
hP-β-cD induces Maturation of human 
Monocyte-Derived Dcs
Maturation of DCs is an essential process for activating 
antigen-specific adaptive immunity and includes the upregula-
tion of costimulatory molecules, MHC class I/II, and certain 
cytokines (12). Thus, we first examined the effects of HP-β-CD 
on the phenotypic maturation and cytokine production in 
human monocyte-derived DCs. Notably, HP-β-CD was not 
cytotoxic to DCs at concentrations up to 1 mg/ml (Figure S1A in 
Supplementary Material). Stimulation with HP-β-CD remark-
ably augmented the expression of costimulatory molecules, 
such as CD80, CD83, and CD86 (Figures  1A,D), together 
with MHC class II (Figures  1B,E). Additionally, HP-β-CD-
treated DCs exhibited increased expression of inhibitory mol-
ecules, such as PD-L1 and PD-L2 (Figures 1C,F). Moreover, 
HP-β-CD weakly increased the expression of proinflammatory 
cytokines, including TNF-α and IL-6, in a dose-dependent 
manner (Figures  1G,H). Furthermore, HP-β-CD treatment 
slightly increased IL-10 expression in DCs (Figure  1I), and 
IL-12p70 was not detected in the culture supernatant of HP-β-
CD-treated DCs (data not shown). These results suggest that 
HP-β-CD upregulates the expression of maturation markers 
coincident with weak induction of cytokines in human 
monocyte-derived DCs.
FigUre 2 | hP-β-cD-sensitized Dcs elicit the proliferation and activation of autologous T lymphocytes. Human monocyte-derived DCs (2.5 × 105 cells/
ml) were stimulated with HP-β-CD (0, 0.1, 0.3, or 1 mg/ml) for 16 h. Then, the cells (5 × 104 cells) were cocultured with CFSE-labeled autologous CD3+ T cells 
(5 × 104 cells) for 4 days. (a) T lymphocyte proliferation and CD25 expression were analyzed by flow cytometry. The bar graph beside the histograms displays the 
average of triplicate measurements for the proliferation of CD25+ T lymphocytes. (B) A scatter plot indicates activated T lymphocytes by DCs (n = 5).  
(c) The proliferation and CD25 expression levels of CD3+, CD4+, or CD8+ T lymphocytes were analyzed by flow cytometry. The bar graphs on the right side of the 
histograms exhibit the average of triplicate measurements for the proliferation of CD25+ T lymphocytes. (D) Scatter plots exhibit activated CD3+, CD4+, or CD8+ 
T lymphocytes by DCs (n = 3). The immune responses of T lymphocytes cultured with HKEC-stimulated DCs are shown as positive controls. The numbers on the 
histograms indicate the percentages of T lymphocytes in each quadrant. *P < 0.05. Unstim.-DC indicates T lymphocytes cocultured with unstimulated DCs.
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hP-β-cD-sensitized Dcs elicit autologous 
T lymphocyte Proliferation and activation
To examine whether HP-β-CD potentiates the T lymphocyte-
activating ability of DCs, unstimulated or HP-β-CD-stimulated 
DCs were cocultured with autologous T lymphocytes, and 
the extents of T lymphocyte proliferation and activation were 
analyzed. HP-β-CD-sensitized DCs significantly induced 
T lymphocyte proliferation and CD25 expression, an activation 
marker of T lymphocytes (Figures  2A,B). The enhancement 
of proliferation and CD25 expression was observed in CD4+ 
T lymphocytes but not in CD8+ T lymphocytes (Figures 2C,D). 
However, HP-β-CD did not directly enhance the proliferative 
activity or CD25 expression of the T lymphocytes, indicating that 
HP-β-CD requires the help of DCs to activate T lymphocytes 
(Figures S2A,B in Supplementary Material). Therefore, the 
results suggest that HP-β-CD potentiates the ability of DCs to 
induce CD4+ cells.
hP-β-cD Triggers lipid raft Formation  
on the Dc Plasma Membrane
Lipid rafts are hydrophobic microstructures that play an impor-
tant role as signal transduction platforms in many eukaryotic 
cells (20). Since HP-β-CD interacts with cellular cholesterol 
(21), an essential component of lipid rafts, we examined whether 
HP-β-CD induces lipid raft formation on the plasma membrane 
based on the hypothesis that lipid rafts are involved in the 
HP-β-CD-induced DC maturation. DCs were stimulated with 
HP-β-CD in the presence or absence of filipin, which disrupts 
FigUre 3 | hP-β-cD triggers lipid raft formation in Dcs. Human monocyte-derived DCs (2.5 × 105 cells/ml) were stimulated with HP-β-CD (1 mg/ml) in the 
presence or absence of filipin (30 μg/ml) or methanol as a vehicle control for 45 min. (a) Stimulated DCs were stained with Alexa Fluor® 594-conjugated CTB, and 
the formation of lipid rafts on the cell surface was examined by confocal microscopy. (B) Fluorescence intensity of DCs was analyzed by ZEN software. DIC, 
differential interference contrast; AU, arbitrary unit. Images shown are representative of three similar results.
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a lipid raft formation, and fluorochrome-conjugated CTB was 
used to detect the formation of lipid rafts. As shown in Figure 3, 
HP-β-CD triggered lipid raft formation on the surface of DCs, 
whereas such effect was blocked by preexposure to the lipid raft 
inhibitor filipin.
inhibition of lipid raft Formation reduces 
hP-β-cD-induced Dc Maturation
Next, we further determined the role of lipid rafts in HP-β-CD-
mediated DC maturation by blocking the lipid raft formation 
using filipin. Of note, treatment with filipin and/or HP-β-CD was 
not cytotoxic to DCs (Figure S1B in Supplementary Material). 
As shown in Figures  4A–C, treatment with filipin remarkably 
attenuated HP-β-CD-elicited expression of surface costimula-
tory molecules, PD-L1/L2, but not MHC class II. In addition, 
HP-β-CD-mediated induction of TNF-α, IL-6, and IL-10 in 
DCs was significantly reduced upon the inhibition of lipid raft 
(Figure 4D). Furthermore, lipid raft inhibition in DCs stimulated 
with HP-β-CD abrogated their ability to activate T lymphocytes 
(Figure  4E). These results suggest that HP-β-CD requires the 
formation of lipid rafts to trigger DC maturation and further to 
activate T lymphocytes.
hP-β-cD Potentiates humoral immune 
responses to coadministered antigens 
and Dc activation in the Draining lymph 
nodes in Mice
Next, we determined whether HP-β-CD has an adjuvanticity 
with a mouse footpad immunization model (22). To immunize 
mice, OVA with or without HP-β-CD was injected through a 
hind footpad, and titers of serum antibodies specific to OVA 
were determined. Coadministration with HP-β-CD and OVA 
efficiently increased OVA-specific total IgG in the blood 
(Figure S3A in Supplementary Material). IgG1 was the major 
antibody subtype induced following immunization (Figure S3B 
in Supplementary Material), and no IgG2a antibodies were 
detected (data not shown). As DCs are crucial in the media-
tion of naive T cell responses, we subsequently analyzed DC 
populations in the draining lymph nodes, including popliteal 
and inguinal lymph nodes upon administration of OVA with 
or without HP-β-CD. Mice administered with OVA with 
HP-β-CD showed an increase in the size and cell number of 
the draining lymph nodes (Figure  5A). OVA administration 
with HP-β-CD markedly augmented the number of CD11c+ 
MHC class II+ cells in the popliteal and inguinal lymph nodes 
(Figures 5B,C). In addition, the DCs showed an upregulation 
in the expression of costimulatory molecules, including CD80 
and CD86 (Figures 5D,E). To determine whether DC activation 
in the draining lymph nodes of mice administered with OVA 
and HP-β-CD is directly attributed to stimulatory functions of 
HP-β-CD, we examined HP-β-CD effects on the maturation of 
BM-DCs generated in vitro. HP-β-CD markedly upregulated the 
expression of surface costimulatory molecules, such as CD80, 
CD83, and CD86, and MHC class II (Figure 5F). In addition, 
HP-β-CD-treated BM-DCs modestly increased the production 
of proinflammatory cytokines including TNF-α and IL-6 in 
BM-DCs compared to LPS-stimulated BM-DCs (Figure  5G). 
Collectively, these results suggest that HP-β-CD-induced DC 
maturation and activation in vivo that might be necessary for 
the adjuvanticity.
DiscUssiOn
Dendritic cells play a pivotal role in the induction of antigen-
specific adaptive immune response by presenting the antigens to 
FigUre 4 | inhibition of lipid raft formation attenuates Dc maturation, cytokine production, and autologous T cell activation induced by hP-β-cD. 
Human monocyte-derived DCs (2.5 × 105 cells/ml) were pretreated with filipin (10 and 30 μg/ml) or methanol as a vehicle control for 1 h, followed by stimulation with 
HP-β-CD (1 mg/ml) for another 24 h. (a–c) The expression of costimulatory molecules, MHC class II, and PD-L1/L2 was analyzed by flow cytometry. The numbers 
on the histograms indicate the MFIs of the cells. Scatter plots under the histogram show MFI of DCs (n = 5). Statistical differences between compared groups were 
analyzed by paired Student’s t-test. N.S., not significant; *P < 0.05. (D) The concentrations of TNF-α, IL-6, and IL-10 in the supernatants were measured by ELISA. 
(e) Unstimulated or HP-β-CD-stimulated DCs (5 × 104 cells) were cocultured with CFSE-labeled autologous T lymphocytes (5 × 104 cells) for 5 days. The levels of 
proliferation and CD25 expression of the T lymphocytes were analyzed by flow cytometry. The numbers on the histograms indicate the percentages of cells in each 
quadrant. The bar graph below the histograms displays the average of triplicate measurements ± SD for the frequencies of CD25+ T lymphocytes with proliferative 
ability. Unstim.-DC indicates T lymphocytes cocultured with unstimulated DCs. Results shown are representative of three independent experiments. Statistical 
differences between compared groups were analyzed by Student’s t-test. N.D., not detected; *P < 0.05.
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T cells and activating appropriate subtypes of T cells. HP-β-CD 
has long been utilized as a solubilizer and a delivery compound 
of hydrophobic drugs due to its physicochemical properties (6). 
However, recent studies have reported a novel beneficial effect of 
HP-β-CD on the immunogenicity of vaccines (7, 23) as well as on 
the progression of incurable metabolic disorders (24) and viral 
infections (25). Although the previous findings have suggested 
that HP-β-CD could be a potential vaccine adjuvant (7, 23), the 
effects of HP-β-CD on vaccine immunogenicity and DC proper-
ties have been poorly investigated. Here, we demonstrated that 
HP-β-CD has an adjuvanticity to OVA, and the maturation of 
DCs found in the draining lymph nodes in a mouse footpad 
immunization model. In vitro studies showed that HP-β-CD 
induces the maturation of DCs to induce the proliferation and 
activation of autologous T lymphocytes. Mechanism studies 
further showed that the lipid raft formation in DCs is essential for 
FigUre 5 | hP-β-cD induces Dc maturation and activation in vivo and in vitro mouse models. C57BL/6 mice were immunized with 20 μg OVA in the 
presence or absence of 3 mg HP-β-CD through a hind footpad. Twenty-four hours after the immunization, DC populations were analyzed in the draining lymph 
nodes including popliteal and inguinal lymph nodes. (a) Size of the lymph nodes and the total cell numbers were measured (n = 4). CD11c+ MHC class II+ cells in 
the draining lymph nodes, (B) popliteal and (c) inguinal lymph nodes were analyzed by flow cytometry (n = 4). Expression of CD80 and CD86 on CD11c+ cells was 
analyzed in the draining lymph nodes, (D) popliteal and (e) inguinal lymph nodes by flow cytometry. Scatter plots on the right side the histograms indicate MFI of 
DCs for CD80 (n = 4) and CD86 (n = 3). (F) BM-DCs (5 × 105 cells/ml) were stimulated with HP-β-CD (0.1 or 1 mg/ml) or LPS (100 ng/ml) in the presence of murine 
GM-CSF for 24 h. The surface expression of various maturation markers, including (F) CD80, CD83, CD86, and MHC class II molecules on the DCs, was analyzed 
by flow cytometry. (g) The amounts of TNF-α and IL-6 in the culture supernatants of DCs were quantified by ELISA. The number on each histogram indicates 
percentage or MFI of the DCs. LN, lymph node. N.D., not detected. N.S., not significant. *P < 0.05. The result shown is a representative of four similar experiments.
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the HP-β-CD-induced DC maturation and its subsequent activa-
tion of autologous T cells. These results suggest that HP-β-CD is 
a promising vaccine adjuvant to potently induce the maturation 
and activation of DCs.
In the present study, we demonstrated that HP-β-CD has an 
adjuvanticity. Administration of HP-β-CD efficiently augmented 
the antigen-specific IgG in the blood. Notably, HP-β-CD pre-
dominantly induced IgG1 but not IgG2, indicating preferential 
enhancement of Th2 responses rather than Th1 responses. 
Consistent with our findings, intranasal or subcutaneous admin-
istration of HP-β-CD increased the immunogenicity of influenza 
vaccines (7, 23). HP-β-CD seems to be appropriate as a mucosal 
adjuvant because it induces antigen-specific IgA and IgG in the 
airway mucosal tissues as well as in the blood (23).
Dendritic cell maturation is a prerequisite for the induction 
of adaptive immune response. Many previous studies have 
demonstrated that current vaccine adjuvants, such as aluminum 
salt (alum), cholera toxin (CT), and monophosphoryl lipid 
A (MPLA), can efficiently induce DC maturation (26–28). Here, 
we observed that HP-β-CD increased DCs in the draining lymph 
nodes as well as the upregulation of DC costimulatory molecules 
when coadministered with antigen. Additionally, HP-β-CD 
induced a marked increase in the expression of CD80, CD83, 
CD86, and MHC proteins on BM-DCs and human monocyte-
derived DCs. Furthermore, stimulation with HP-β-CD resulted 
in weak but significant production of TNF-α, IL-6, and IL-10 
in DCs. Therefore, like other adjuvants, HP-β-CD appears to be 
capable of stimulating DC maturation. However, in contrast to our 
9Kim et al. DC Maturation by HP-β-CD
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observation, a previous study found that HP-β-CD did not induce 
a maturation marker of CD11c+ DCs in the draining lymph node, 
even though it potentiated DC antigen uptake (7). Given the dif-
ferences in a route of injection and doses of HP-β-CD, functional 
mode of DC activation in the tissues might be different.
Here, we found that HP-β-CD-sensitized DCs markedly 
induced the proliferation and activation of T lymphocytes, 
especially CD4+ cells, implying that HP-β-CD can potentially 
enhance Th-dependent immune responses. Notably, a study 
of mice immunized with an influenza vaccine suggested that 
HP-β-CD is a competent adjuvant capable of eliciting folli-
cular Th cells and antibody production (7). Furthermore, other 
cyclodextrins, such as sulfolipo-cyclodextrin and dimethyl-β-
cyclodextrin, have been found to enhance antibody responses 
in a T lymphocyte-dependent manner (29, 30). Given the fact 
that enhanced T cell responses have previously been observed 
with many existing adjuvants, including MPLA, saponin, and 
CT (31, 32), this enhancement appeared to be mediated through 
DC activation. These adjuvants influence the types of adaptive 
immune responses that occur by modulating T lymphocyte 
differentiation. For instance, alum is an established potentiator 
of Th2-mediated humoral immunity (33). In addition, MPLA 
has been shown to preferentially induce Th1-skewed immune 
responses (34), whereas CT provokes Th1, Th17, and Th2 
responses (35). Considering the previous finding that HP-β-CD 
administration markedly induces IL-13 and IL-5 production, 
HP-β-CD has been proposed to elicit Th2 responses (7).
In the present study, we observed that HP-β-CD-induced lipid 
raft formation and contributed to DC maturation. Specifically, 
filipin-mediated inhibition of lipid rafts abrogated HP-β-CD-
mediated phenotypic changes and functional activation of 
DCs. In line with this observation, many previous studies have 
demonstrated lipid raft involvement in the activation of various 
immune cells. Dispersion of lipid rafts has been shown to impair 
CD1a-mediated antigen presentation by DCs and subsequent 
activation of T lymphocytes (36). Furthermore, alum adjuvan-
ticity has been proposed to have a critical relationship with the 
formation of signaling platforms via lipid sorting on DCs (26).
2-Hydroxypropyl-β-cyclodextrin can interact with cellular 
cholesterol (21); however, the precise effects of HP-β-CD on 
cholesterol seem to depend on its concentration. Low doses 
of HP-β-CD (below 1  mM) induce efflux or intermembrane 
transport of cholesterol, while high concentrations (10–100 mM) 
deplete the lipid molecules from the cell membrane (37, 38). In the 
present study, DCs were treated with up to 1 mg/ml HP-β-CD, 
which is equivalent to 1.4 mM. This concentration is relatively 
low and is likely to mediate cholesterol accumulation and lipid 
raft formation on the cell membrane rather than to deplete cho-
lesterol. In light of the observation that cholesterol accumulation 
in the membrane of human monocytes promotes the association 
of immuno-stimulatory receptor complexes, cholesterol loading 
in the plasma membrane is believed to be crucial for eliciting 
inflammatory immune responses (39). Since HP-β-CD can trans-
port free cholesterol to the plasma membrane (40), HP-β-CD is 
likely to play a role in the formation of cholesterol-rich lipid rafts 
in DCs, thereby activating signals required for their phenotypic 
and functional maturation.
Recently, potential issues in relation to the efficacy and safety 
of vaccine adjuvant have been raised (41–44). Thus, demand has 
increased for new adjuvants with minimal adverse effects and 
enhanced capacity to stimulate antigen-specific adaptive immune 
responses. HP-β-CD is GRAS in many Asian and European 
countries and is already widely utilized in various commercial 
products, including food and drugs. Our findings potentially 
inform the future application and improvement of vaccine adju-
vants with HP-β-CD.
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